Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.

Cancer research and treatment - 1 Oct 2023

Lee Sung Hwan, Cheon Jaekyung, Lee Seoyoung, Kang Beodeul, Kim Chan, Shim Hyo Sup, Park Young Nyun, Jung Sanghoon, Choi Sung Hoon, Choi Hye Jin, Lee Choong-Kun, Chon Hong Jae

Abstract excerpt

PURPOSE: There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC. MATERIALS AND METHODS: Genomic analysis of advanced BTC multi-institutional cohorts was performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Cisplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to High-Throughput Nucleotide Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 37139666
DOI: 10.4143/crt.2022.1450
PMCID: PMC10582529

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.PMID 37139666Read ↗

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Semantic proximity Read ↗

Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer.Semantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.Semantic proximity Read ↗

Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer.Semantic proximity Read ↗

Biliary cancer: Utility of next-generation sequencing for clinical management.Semantic proximity Read ↗

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancerSemantic proximity Read ↗

Mutational spectrum and precision oncology for biliary tract carcinoma.Semantic proximity Read ↗

Real-world Analysis of Treatment Patterns, Clinical Outcomes, and Molecular Profiling in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Molecular profiling of biliary tract cancer: a target rich diseaseSemantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.